Metformin: Is it a drug for all reasons and diseases?

Clinical and experimental (2022), this meta-analysis evaluating human clinical outcomes investigated: Metformin was first used to treat type 2 diabetes in the late 1950s and in 2022 remains the first-choice drug used daily by approximately 150 million people. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

To find out, researchers writing in Metabolism: clinical and experimental conducted a meta-analysis evaluating multiple clinical patient groups. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

We conclude that the primary clinical benefits of metformin result from its insulin-sensitizing and antihyperglycaemic effects that secondarily contribute to a reduced risk of a number of diseases and thereby enhancing healthspan. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.